These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38660851)
1. [Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance]. Qu Y; Lu XZ; Wang RX; Hei XF; Li J; Xiao BT; Jia ZX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):450-457. PubMed ID: 38660851 [TBL] [Abstract][Full Text] [Related]
2. [Expression of CD30 in Diffuse Large B Cell Lymphoma and Its Clinical Significance]. Zhao YF; Qian SX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):717-21. PubMed ID: 27342497 [TBL] [Abstract][Full Text] [Related]
3. [Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance]. Wang M; Zhang PP; Zhu Q; Hu ZL; Bai X; Wu YP; Li JJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):112-119. PubMed ID: 38387908 [TBL] [Abstract][Full Text] [Related]
4. [Prognosis analysis of primary breast diffuse large B cell lymphoma]. Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462 [No Abstract] [Full Text] [Related]
5. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma]. Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579 [No Abstract] [Full Text] [Related]
6. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma]. Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. Huang H; Fan L; Fu D; Lin Q; Shen J Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457 [TBL] [Abstract][Full Text] [Related]
8. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma]. Wen JJ; Liu ZB; Xu J; Xu CG Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791 [TBL] [Abstract][Full Text] [Related]
9. [Expression and Clinical Significance of Exosome Component 4 in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma]. Hong JQ; Huang QH; Huang ZY; Fan LP; Lin QY; Huang HB Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1684-1689. PubMed ID: 38071046 [TBL] [Abstract][Full Text] [Related]
10. [The clinical characteristics and prognostic analysis of 147 cases of diffuse large B-cell lymphoma]. Zhao Q; Fu WJ; Zhang CY; Du J; Xi H; Hou J Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):737-40. PubMed ID: 24103868 [TBL] [Abstract][Full Text] [Related]
11. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients. Wu XB; Hou SL; Liu H World J Clin Cases; 2021 Nov; 9(32):9825-9834. PubMed ID: 34877321 [TBL] [Abstract][Full Text] [Related]
12. Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma. Shen N; Yu Y; Zhang R; Guo Y; Liu M; Tan M; Liu J; Bai J; Li L; Liu K; Wang R; He J Int J Clin Pract; 2022; 2022():2637581. PubMed ID: 36567775 [TBL] [Abstract][Full Text] [Related]
13. [Ki-67 proliferative index in non-Hodgkin's lymphoma and its clinical significance]. Li J; Hu R; Liao AJ; Shi HY; Yan W; Liu ZG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):935-9. PubMed ID: 21867618 [TBL] [Abstract][Full Text] [Related]
14. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma]. Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773 [No Abstract] [Full Text] [Related]
15. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study. Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932 [TBL] [Abstract][Full Text] [Related]
16. [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas]. He Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Li JY; Xu W Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):505-510. PubMed ID: 28655094 [No Abstract] [Full Text] [Related]
17. [Clinicopathological features in relapsed diffuse large B-cell lymphoma]. Gong YX; Yang YF; Feng YF; Zhai BY; Zhang X; Zhang ZH Zhonghua Bing Li Xue Za Zhi; 2020 Oct; 49(10):1015-1020. PubMed ID: 32992415 [No Abstract] [Full Text] [Related]
18. [Clinical characteristics and prognostic features of 63 HIV-associated diffuse large B-cell lymphoma: a single-center real-world study in China]. Wang CY; Liu J; Liang XP; Guo BL; Hu RZ; Liu Y Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):203-208. PubMed ID: 35405777 [No Abstract] [Full Text] [Related]
19. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715 [TBL] [Abstract][Full Text] [Related]
20. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]